Your institution may have access to this item. Find your institution then sign in to continue.

Title: Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally.
Authors: Guo, Xuetao; Qiu, Lixia; Wang, Yonghong; Wang, Yue; Meng, Yuanguang; Zhu, Yun; Lu, Lu; Jiang, Shibo
Abstract: Currently, there is no specific antiviral therapy for treatment of HPV infection. Jiang and colleagues previously reported that anhydride-modified proteins have inhibitory activities against multiple viruses including HPV. Here, we evaluated the safety of 3-hydroxyphthalic anhydride-modified bovine beta-lactoglobulin, designated JB01, vaginally applied in women infected by high-risk HPV. After the vaginal application of JB01 in 38 women for 3 months, no serious adverse events were reported, and normalization of the vaginal micro-environment has been observed. It can be concluded that JB01-BD is safe for vaginal use in HPV-infected women, suggesting its potential application for the treatment of HPV infection. J. Med. Virol. 88:1098-1101, 2016. © 2015 Wiley Periodicals, Inc.
Publication: Journal of Medical Virology, 2016, Vol 88, Issue 6, p1098
ISSN: 0146-6615
Publication type: Academic Journal
DOI: 10.1002/jmv.24439

We found a match

Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally.